Alumis (NASDAQ:ALMS) Shares Gap Up After Analyst Upgrade

Alumis Inc. (NASDAQ:ALMS)’s stock price gapped up before the market opened on Wednesday after HC Wainwright upgraded the stock from a neutral rating to a buy rating. The stock had previously closed at $9.47, but opened at $10.16. HC Wainwright now has a $15.00 price target on the stock, down from their previous price target of $25.00. Alumis shares last traded at $10.5690, with a volume of 2,470,158 shares changing hands.

ALMS has been the topic of several other research reports. Wall Street Zen upgraded shares of Alumis from a “strong sell” rating to a “hold” rating in a report on Sunday, August 23rd. Guggenheim upped their target price on Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Wells Fargo & Company reissued an “overweight” rating on shares of Alumis in a research report on Wednesday. Chardan Capital raised their price objective on shares of Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, May 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Alumis currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.91.

Insider Buying and Selling at Alumis

In other Alumis news, insider Mark Christopher Bradley sold 2,572 shares of Alumis stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $67,823.64. Following the completion of the transaction, the insider directly owned 48,533 shares of the company’s stock, valued at $1,279,815.21. The trade was a 5.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jorn Drappa sold 2,447 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $64,527.39. Following the sale, the insider directly owned 56,892 shares of the company’s stock, valued at $1,500,242.04. This represents a 4.12% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 19,953 shares of company stock valued at $534,311 over the last ninety days. 33.70% of the stock is owned by corporate insiders.

More Alumis News

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: HC Wainwright upgraded Alumis from “neutral” to “buy,” citing potential upside from the company’s pipeline. However, the firm reduced its price target to $15 from $25, reflecting the heightened risk following the lupus setback. Benzinga report
• Positive Sentiment: Although the LUMUS trial failed in the overall population, Alumis reported stronger responses among patients with high interferon gene signatures. Management plans to pursue a Phase 3 lupus study in this subgroup and remains on track to submit a psoriasis NDA in the fourth quarter of 2026. Alumis topline results announcement
• Neutral Sentiment: Envudeucitinib was generally well tolerated, with no new safety signals reported. The company also said pharmacodynamic results support the drug’s activity in interferon-driven immune diseases. Reuters report
• Negative Sentiment: The Phase 2b LUMUS study missed both its primary and secondary endpoints in the overall systemic lupus erythematosus population. The failure substantially weakened the near-term lupus opportunity for envudeucitinib and triggered a steep decline in ALMS shares. RTTNews report
• Negative Sentiment: Unusually heavy bearish options activity accompanied the selloff: investors bought 4,619 put options, more than four times typical volume, signaling increased hedging or speculation on further weakness. Trading was also temporarily halted for pending news.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Alumis in the 2nd quarter worth approximately $231,259,000. venBio Partners LLC bought a new position in shares of Alumis in the 2nd quarter worth about $127,429,401. MPM Bioimpact LLC bought a new position in shares of Alumis in the 4th quarter worth about $23,443,000. Jupiter Topco LLC acquired a new position in shares of Alumis in the 2nd quarter valued at about $66,238,000. Finally, California State Teachers Retirement System boosted its holdings in shares of Alumis by 2,643.4% during the 2nd quarter. California State Teachers Retirement System now owns 2,217,939 shares of the company’s stock worth $62,413,000 after buying an additional 2,137,094 shares in the last quarter.

Alumis Trading Up 11.5%

The firm’s 50-day moving average price is $26.20 and its 200 day moving average price is $24.93. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -2.72 and a beta of -0.80.

Alumis (NASDAQ:ALMS) last issued its earnings results on Thursday, August 13th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). Alumis had a negative net margin of 5,933.46% and a negative return on equity of 93.15%. The firm had revenue of $1.66 million during the quarter, compared to the consensus estimate of $3.65 million. Analysts forecast that Alumis Inc. will post -2.95 earnings per share for the current fiscal year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.